// App-Quantinova.ai

POS1038 (2022) : GUSELKUMAB EFFICACY IN PSORIATIC ARTHRITIS ASSESSED BY MULTI-DOMAIN COMPOSITE INDICES: DATA FROM THE PHASE 3B COSMOS TRIAL IN A TNFi-IR POPULATION

Researchers

Presenter

  • L. Gossec

Principal Investigators

  • E. Theander

  • M. Neuhold

  • P. Bergmans

  • M. Shawi

  • M. Perate

  • C. Contre

  • L. Coates

Medical Centers

  • Sorbonne Universite and Pitie-Salpetriere Hospital, Rheumatology, Paris, France

  • Formerly at Janssen Scientific Affairs, LLC, Solna, Sweden

  • Janssen, Scientific Affairs, LLC, Zug, Switzerland

  • Janssen-Cilag BV, Biostatistics, Breda, Netherlands

  • Janssen Pharmaceutical Companies of Johnson & Johnson, Immunology Global Medical Affairs, Horsham, PA, United States of America

  • Janssen Scientific Affairs, LLC, Raritan, United States of America

  • Janssen, Scientific Affairs, LLC, Issy-les-Moulineaux, France

  • Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom

Locations

  • France

  • Sweden

  • Switzerland

  • Netherlands

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Dermatology

Disease

  • Psoriatic arthritis

Biomarkers

  • Malondialdehyde

Drug/Treatment

  • guselkumab (IV)

  • Grace

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • III

Study Id's

  • NCT03796858

Sponsors

  • Amgen

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved